Abstracts Archive - Page 1573 of 2607 - ACR Meeting Abstracts

Abstract Number: 2786 • 2017 ACR/ARHP Annual Meeting
Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Current guidelines recommend holding biologic DMARDs before major surgery, despite limited data. Few studies have examined perioperative timing of individual biologic therapies. This study…
Abstract Number: 2787 • 2017 ACR/ARHP Annual Meeting
Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program
Kevin Winthrop¹, Stephen Lindsey², Masayoshi Harigai³, John D. Bradley⁴, Lei Chen⁴, David L. Hyslop⁴, Maher Issa⁴, Atsushi Nishikawa⁵, Sarah Witt⁴, Christina L. Dickson⁴ and Maxime Dougados⁶, ¹Oregon Health & Science University, Portland, OR, ²Ochsner Health Center, Baton Rouge, LA, ³Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Lilly Japan K.K., Kobe, Japan, ⁶Rene Descartes University, Cochin Hospital, Paris, France
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor approved in the EU for the treatment (trt) of moderately to…
Abstract Number: 2788 • 2017 ACR/ARHP Annual Meeting
The Risk of Major Toxicity with Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis Patients Using Nsaids: A Secondary Cohort Analysis of a Randomized Controlled Clinical Trial
Daniel H. Solomon¹, Peter Libby², Qiuquing Wang³, Katherine E Wolski⁴, Lisa M Wisniewski⁴, Neville Yeomans⁵, Michael Lincoff⁶, Steven E Nissen⁷ and M. Elaine Husni⁸, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁵Western Sydney Medical School, Sydney, Australia, ⁶Cardiology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: There are relatively clear guidelines for the use of low dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit…
Abstract Number: 2789 • 2017 ACR/ARHP Annual Meeting
Deficiency of the Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Induces Replication Stress in RA Fibroblast-like Synoviocytes (FLS) and Exacerbates Arthritis Severity
Shinji Matsuda¹, Deepa Hammaker², Katheryn Topolewski³, Karoline Briegel⁴, Steven Dowdy⁵, David L. Boyle⁶, Wei Wang⁷ and Gary S. Firestein⁸, ¹Medicine, UC San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³UC San Diego, La Jolla, CA, ⁴University of Miami, Miami, FL, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶University of California San Diego, La Jolla, CA, ⁷Chemistry and Biochemistry, UC San Diego, La Jolla, CA, ⁸Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: LBH (Limb-bud and heart development) was recently identified as an RA risk gene that has abnormally methylated loci and a functional enhancer SNP in…
Abstract Number: 2790 • 2017 ACR/ARHP Annual Meeting
Regulation of ASK1 Expression and Its Role in Rheumatoid Arthritis (RA)
Gyrid Nygaard¹, Deepa Hammaker², David L. Boyle³, Li Li⁴, Julie Di Paolo⁵ and Gary S. Firestein⁶, ¹Medicine, UC San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³University of California San Diego, La Jolla, CA, ⁴Gilead Sciences, South San Francisco, CA, ⁵Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ⁶Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) reside in the synovial intimal lining. They display a unique aggressive phenotype, invading the articular cartilage and promoting…
Abstract Number: 2791 • 2017 ACR/ARHP Annual Meeting
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Marginal Jawbone Loss Predates the Onset of Rheumatoid Arthritis
Elin Kindstedt¹, Linda Johansson², Py Palmqvist³, Cecilia Koskinen Holm¹, Heidi Kokkonen⁴, Ingegerd Johansson³, Pernilla Lundberg³ and Solbritt Rantapaa-Dahlqvist⁵, ¹1Department of Odontology/Molecular Periodontology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department of Odontology/Molecular Periodontology, Umeå University, Umeå, Sweden, ⁴Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Dept of Public Health and Clinical Medicine/Rheumatology, Umeå University, Sweden, Umeå, Sweden
Background/Purpose: Previous studies have shown a higher incidence of alveolar bone loss in patients with rheumatoid arthritis (RA) and that patients with periodontitis are at…
Abstract Number: 2792 • 2017 ACR/ARHP Annual Meeting
Th22 Cells Are a Potent Inducer of Osteoclastogenesis in Rheumatoid Arthritis
Yusuke Miyazaki¹, Shingo Nakayamada², Satoshi Kubo¹, Kazuhisa Nakano², Kei Sakata³, Shigeru Iwata⁴, Ippei Miyagawa⁵ and Yoshiya Tanaka⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyshu, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: CD4+ T cells can differentiate into functionally distinct subsets and play a pivotal role in rheumatoid arthritis (RA). Th22 cells have been identified as…
Abstract Number: 2793 • 2017 ACR/ARHP Annual Meeting
Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)
Deepa Hammaker¹, Gyrid Nygaard¹, David L. Boyle², Rizi Ai³, Wei Wang⁴ and Gary S. Firestein⁵, ¹Medicine, UC San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³UC San Diego, La Jolla, CA, ⁴Chemistry and Biochemistry, UC San Diego, La Jolla, CA, ⁵Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Aberrant epigenetic marks in RA FLS contribute to disease pathogenesis and aggressive FLS behavior. Computational data also suggest that RA FLS isolated from different…
Abstract Number: 2794 • 2017 ACR/ARHP Annual Meeting
Apolipoprotein B Binds to Enolase-1 and Aggravates Inflammation in Rheumatoid Arthritis
Joo Youn Lee¹, Min Jueng Kang¹, Ji Yong Choi², Ji Soo Park³, Jin Kyun Park^1,2, Eun Young Lee⁴, Eun Bong Lee⁵, Thomas Pap⁶, Eugene Yi¹ and Yeong Wook Song^1,2, ¹Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ³Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, seoul, Korea, Republic of (South), ⁶Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial inflammation and joint destruction. Monocytes and synovial macrophages are key players in…
Abstract Number: 2795 • 2017 ACR/ARHP Annual Meeting
Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study
Hans-Peter Tony¹, Hendrik Schulze-Koops², Klaus Krüger³, Stanley B Cohen⁴, Alan J. Kivitz⁵, Slawomir Jeka⁶, Edit Vereckei⁷, Liyi Cen⁸ and Dmitrij Kollins⁸, ¹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ³Praxiszentrum St. Bonifatius München, München, Germany, ⁴Metroplex Clinical Research Centre, Dallas, TX, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, ⁷National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁸Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany
Background/Purpose: GP2013, is a biosimilar to European Union (EU) approved reference rituximab (RTX), developed in a stepwise approach that adheres to stringent biosimilar development guidelines.…
Abstract Number: 2796 • 2017 ACR/ARHP Annual Meeting
A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Stanley B Cohen², Morton Scheinberg³, Tamas Shisha⁴, Dmitrij Kollins⁴, Peijuan Zhu⁵, Liyi Cen⁴, Alan J. Kivitz⁶, Andra Rodica Balanescu⁷, Juan J. Gomez-Reino⁸ and Hans-Peter Tony⁹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Metroplex Clinical Research Centre, Dallas, TX, ³Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, ⁴Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, ⁵Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Research Center of Rheumatic Diseases, “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, ⁸BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, ⁹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Rituximab (RTX) is a mAB indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy. The current study compares the…
Abstract Number: 2797 • 2017 ACR/ARHP Annual Meeting
Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
Arthur Kavanaugh¹, Yannick Allanore², Eugeniusz J. Kucharz³ and Goran Babic⁴, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, ³Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland, ⁴Clinical development, Biopharmaceuticals, Hexal AG, a Sandoz company, Holzkirchen, Germany
Background/Purpose: The biosimilarity of GP2015 and etanercept originator product (ETN) has been previously demonstrated in patients with chronic plaque-type psoriasis.1 The randomized, double-blind, phase 3…
Abstract Number: 2798 • 2017 ACR/ARHP Annual Meeting
A Randomized, Double-Blind Study Comparing PF-06438179/GP1111, a Potential Infliximab Biosimilar, and Infliximab, Both in Combination with MTX, As Treatment for Patients with Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Therapy
Stanley B Cohen¹, Rieke Alten², Hideto Kameda³, Muhammad I. Rehman⁴, Karl Schumacher⁵, Susanne Schmitt⁵, Steven Y. Hua⁶ and K. Lea Sewell⁷, ¹Metroplex Clinical Research Center, Dallas, TX, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ⁴Pfizer Inc, Andover, MA, ⁵Global Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany, ⁶Pfizer Inc, San Diego, CA, ⁷Biosimilars Development, Pfizer Inc, Cambridge, MA
Background/Purpose: This double-blind, randomized study evaluated efficacy, safety and immunogenicity of PF‑06438179/GP1111, a potential infliximab biosimilar, vs infliximab sourced from the EU (infliximab-EU) in patients…
Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting
Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)
Mark C. Genovese¹, Josephine Glover², Nobuhito Matsunaga³, Diane Chisholm⁴ and Rieke Alten⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, ³Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, ⁴Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, ⁵University Medicine Berlin, Berlin, Germany
Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
Abstract Number: 2800 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Joe Sexton¹, Inge C Olsen³, Nils Bolstad⁴, Merete Lorentzen⁵, Espen A. Haavardsholm⁶, Cato Mork⁷, Jorgen Jahnsen⁸ and Tore K Kvien⁹, ¹Dept Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of cancer and Molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway, ⁸Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁹Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) , Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].